Recently, a novel Cav therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF) has been developed based on the delivery of small fragment of the Cav scaffolding domain (7 amino acids from 89–95 called CSP7) that is effective in models of pulmonary fibrosis.21 The gene discussed is CAV1; the disease is pulmonary fibrosis.